Welcome to our dedicated page for IQVIA Holdings news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
Rhea-AI Summary
IQVIA (NYSE:IQV) releases its 2023 Environmental, Social, and Governance (ESG) Report, highlighting its focus on reducing environmental impact and promoting positive health outcomes. The report showcases the company's commitment to innovation and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
-
Rhea-AI Summary
Global biopharma R&D productivity rebounded in 2023, with higher composite success rates due to industry-wide adoption of data-driven innovation. Clinical trial starts returned to pre-pandemic levels, focusing on newer modalities like cell and gene therapy, neurology, and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. announces CFO Ron Bruehlman to speak at Citi's 2024 Unplugged Medtech and Life Sciences Access Day. The presentation will be available via live audio webcast on February 29, 2024, at 9:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
Rhea-AI Summary
IQVIA Holdings Inc. reported a strong financial performance for the fourth quarter of 2023, with revenue reaching $3,868 million, GAAP Net Income of $469 million, and Adjusted EBITDA of $966 million. The company provided a full-year 2024 revenue guidance of $15,400 million to $15,650 million, showcasing positive growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
-
Rhea-AI Summary
IQVIA has been named to the Fortune World's Most Admired Companies list for the seventh consecutive year, earning the first-place ranking within the Health Care: Pharmacy and Other Services category for the third year in a row. The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets. Fortune's Most Admired Companies is a prestigious report card on corporate reputation, highlighting the business practices that make these companies highly regarded among their peers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. will release its fourth-quarter and full-year 2023 financial results on February 14, 2024. The management team will host a conference call and webcast. The earnings release and financial information will be posted on the IQVIA Investor Relations website. Interested parties can participate in the conference call by registering in advance. A replay of the webcast will be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
Rhea-AI Summary
The IQVIA Institute for Human Data Science report projects a 2 percentage point increase in growth outlook for global spending and demand for medicines, reaching approximately $2.3 trillion by 2028. This is driven by more patients getting access to new and better medicines, particularly in immunology, endocrinology, and oncology. The report also highlights lower expectations for COVID-19 vaccines and therapeutics, resulting in a $200 billion reduction in eight-year cumulative spending estimates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary
IQVIA (NYSE:IQV) has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category for its Digital Enablement division. The award recognizes outstanding achievement and innovation in healthcare marketing, with a focus on innovation, talent development, and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. (IQV) announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on November 29, 2023, at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com, with a replay available later that day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
Rhea-AI Summary
IQVIA Holdings Inc. (NYSE:IQV) announces allocation of a new term B loan due 2031 of approximately $1,500 million, upsized due to lender demand. The loan, along with senior secured notes, will be used to repay existing loans and related fees. The Company also entered into a cross-currency swap agreement to hedge exposure to USD-denominated indebtedness, resulting in an effective net borrowing rate of 4.9015%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of IQVIA Holdings (IQV)?
The current stock price of IQVIA Holdings (IQV) is $201.82 as of November 22, 2024.
What is the market cap of IQVIA Holdings (IQV)?
The market cap of IQVIA Holdings (IQV) is approximately 36.0B.
What is IQVIA Holdings Inc.?
IQVIA Holdings Inc. is a global leader in integrated information and technology solutions, formed from the merger of Quintiles and IMS Health in 2016.
What services does IQVIA offer?
IQVIA offers services in research and development, technology and analytics, and contract sales for the healthcare industry.
How many employees does IQVIA have?
IQVIA has approximately 50,000 employees operating in more than 100 countries.
What is IQVIA's focus in the research and development segment?
IQVIA's R&D segment focuses on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms.
What is the role of IQVIA's technology and analytics segment?
This segment provides aggregated information and technology services, including data and analytics capabilities for clinical trials, to clients in the healthcare industry.
Does IQVIA conduct virtual clinical trials?
Yes, IQVIA conducts virtual clinical trials as part of its technology and analytics services.
What industries does IQVIA serve?
IQVIA serves pharmaceutical companies, healthcare providers, payers, and policymakers.
How does IQVIA protect patient privacy?
IQVIA is a global leader in protecting individual patient privacy while using healthcare data to deliver real-world insights.
Where can I find more information about IQVIA?
For more information, visit IQVIA's official website: www.quintilesims.com.
When was IQVIA formed?
IQVIA was formed in 2016 from the merger of Quintiles and IMS Health.
IQVIA Holdings Inc.
NYSE:IQV
IQV Rankings
IQV Stock Data
35.96B
179.82M
0.92%
94.4%
1.44%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States of America
DURHAM